| Year |
Citation |
Score |
| 2023 |
Robinson T, Escara-Wilke J, Dai J, Zimmermann J, Keller ET. A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis. The Prostate. PMID 37244751 DOI: 10.1002/pros.24584 |
0.453 |
|
| 2023 |
Jo J, Salfi E, Folz J, Udager AM, Keller E, Kopelman R, Kothapalli SR, Xu G, Wang X. Photoacoustic Spectral Analysis for Evaluating the Aggressiveness of Prostate Cancer Labeled by Methylene Blue Polyacrylamide Nanoparticles. Biosensors. 13. PMID 36979615 DOI: 10.3390/bios13030403 |
0.377 |
|
| 2022 |
Mendoza-Reinoso V, Schnepp PM, Baek DY, Rubin JR, Schipani E, Keller ET, McCauley LK, Roca H. Bone Marrow Macrophages Induce Inflammation by Efferocytosis of Apoptotic Prostate Cancer Cells via HIF-1α Stabilization. Cells. 11. PMID 36496973 DOI: 10.3390/cells11233712 |
0.342 |
|
| 2022 |
Li Q, Sun X, Yu K, Lv J, Miao C, Yang J, Wang S, Fu Z, Sun Y, Zhang H, Zhang ZS, Keller ET, Yao Z, Wang Q. Enterobacter ludwigii protects DSS-induced colitis through choline-mediated immune tolerance. Cell Reports. 40: 111308. PMID 36044853 DOI: 10.1016/j.celrep.2022.111308 |
0.409 |
|
| 2022 |
Ahmed AA, Strong MJ, Zhou X, Robinson T, Rocco S, Siegel GW, Clines GA, Moore BB, Keller ET, Szerlip NJ. Differential immune landscapes in appendicular versus axial skeleton. Plos One. 17: e0267642. PMID 35476843 DOI: 10.1371/journal.pone.0267642 |
0.338 |
|
| 2022 |
Aw Yong KM, Horst E, Neale D, Royzenblat S, Lahann J, Greineder C, Weivoda M, Mehta G, Keller ET. A Bioreactor for 3D Modeling of the Mechanical Stimulation of Osteocytes. Frontiers in Bioengineering and Biotechnology. 10: 797542. PMID 35402411 DOI: 10.3389/fbioe.2022.797542 |
0.313 |
|
| 2021 |
Shelley G, Dai J, Keller JM, Keller ET. Pheno-SELEX: Engineering Anti-Metastatic Aptamers through Targeting the Invasive Phenotype Using Systemic Evolution of Ligands by Exponential Enrichment. Bioengineering (Basel, Switzerland). 8. PMID 34940365 DOI: 10.3390/bioengineering8120212 |
0.311 |
|
| 2021 |
Schnepp PM, Ahmed A, Escara-Wilke J, Dai J, Shelley G, Keller J, Mizokami A, Keller ET. Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer. Bmc Cancer. 21: 1316. PMID 34879849 DOI: 10.1186/s12885-021-09048-0 |
0.319 |
|
| 2021 |
Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D, Deng J, Zhang J. Author Correction: Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Scientific Reports. 11: 15201. PMID 34285337 DOI: 10.1038/s41598-021-94623-5 |
0.32 |
|
| 2021 |
Xu JJ, Thurston SE, Robinson TJ, Escara-Wilke JF, Daignault-Newton S, Martin TL, Keller ET, Keller JM. Effects of Analgesics on Tumor Growth in Mouse Models of Prostate Cancer Bone Metastasis. Journal of the American Association For Laboratory Animal Science : Jaalas. PMID 33952382 DOI: 10.30802/AALAS-JAALAS-20-000060 |
0.307 |
|
| 2021 |
Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS. Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer. Cancer Research. 81: 1623. PMID 33723003 DOI: 10.1158/0008-5472.CAN-21-0464 |
0.362 |
|
| 2021 |
Dai J, Shupp AB, Bussard KM, Keller ET. Extracellular Vesicles and Bone-Associated Cancer. Current Osteoporosis Reports. PMID 33638774 DOI: 10.1007/s11914-021-00668-w |
0.313 |
|
| 2021 |
Kolb AD, Dai J, Keller ET, Bussard KM. 'Educated' Osteoblasts Reduce Osteoclastogenesis in a Bone-Tumor Mimetic Microenvironment. Cancers. 13. PMID 33445695 DOI: 10.3390/cancers13020263 |
0.302 |
|
| 2020 |
Jo J, Siddiqui J, Zhu Y, Ni L, Kothapalli SR, Tomlins SA, Wei JT, Keller ET, Udager AM, Wang X, Xu G. Photoacoustic spectral analysis at ultraviolet wavelengths for characterizing the Gleason grades of prostate cancer. Optics Letters. 45: 6042-6045. PMID 33137064 DOI: 10.1364/OL.409249 |
0.329 |
|
| 2020 |
Tanaudommongkon I, Tanaudommongkon A, Prathipati P, Nguyen JT, Keller ET, Dong X. Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells. Biomedicines. 8. PMID 32751450 DOI: 10.3390/Biomedicines8080253 |
0.365 |
|
| 2020 |
Schnepp PM, Shelley G, Dai J, Wakim N, Jiang H, Mizokami A, Keller ET. Single Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells. Molecular Cancer Research : McR. PMID 32513898 DOI: 10.1158/1541-7786.Mcr-20-0051 |
0.385 |
|
| 2020 |
Guo Y, Wang J, Zhou K, Lv J, Wang L, Gao S, Keller ET, Zhang ZS, Wang Q, Yao Z. Cytotoxic necrotizing factor 1 promotes bladder cancer angiogenesis through activating RhoC. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 32314833 DOI: 10.1096/Fj.201903266Rr |
0.422 |
|
| 2020 |
Smith DC, Daignault-Newton S, Grivas P, Reichert ZR, Hussain M, Cooney KA, Caram M, Alva A, Jacobson J, Yablon C, Mehra R, Escara-Wilke J, Shelley G, Keller ET. Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. PMID 32299729 DOI: 10.1016/J.Clgc.2019.10.019 |
0.506 |
|
| 2020 |
Wu S, Zhang H, Fouladdel S, Li H, Keller E, Wicha MS, Omenn GS, Azizi E, Guan Y. Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing. Computational and Structural Biotechnology Journal. 18: 676-685. PMID 32257051 DOI: 10.1016/J.Csbj.2020.03.005 |
0.395 |
|
| 2020 |
Zhu L, Tang Y, Li XY, Keller ET, Yang J, Cho JS, Feinberg TY, Weiss SJ. Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases. Science Translational Medicine. 12. PMID 32024800 DOI: 10.1126/Scitranslmed.Aaw6143 |
0.357 |
|
| 2020 |
Owen S, Lo T, Fouladdel S, Zeinali M, Keller E, Azizi E, Ramnath N, Nagrath S. Abstract B36: Identifying single-cell gene expression and EGFR mutation profile heterogeneity in NSCLC patients’ CTCs Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Liqbiop20-B36 |
0.342 |
|
| 2019 |
Osawa T, Wang W, Dai J, Keller ET. Macrofluidic recirculating model of skeletal metastasis. Scientific Reports. 9: 14979. PMID 31628348 DOI: 10.1038/S41598-019-50577-3 |
0.422 |
|
| 2019 |
Dai J, Escara-Wilke J, Keller JM, Jung Y, Taichman RS, Pienta KJ, Keller ET. Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. The Journal of Experimental Medicine. PMID 31548301 DOI: 10.1084/Jem.20190158 |
0.508 |
|
| 2019 |
Ganguly SS, Hostetter G, Tang L, Frank SB, Saboda K, Mehra R, Wang L, Li X, Keller ET, Miranti CK. Notch3 promotes prostate cancer-induced bone lesion development via MMP-3. Oncogene. PMID 31467432 DOI: 10.1038/S41388-019-0977-1 |
0.514 |
|
| 2019 |
Guo H, Wang F, Diao Y, Zhang Z, Chen Q, Qian CN, Keller ET, Zhang J, Lu Y. Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA. Molecular Carcinogenesis. PMID 31270884 DOI: 10.1002/Mc.23082 |
0.391 |
|
| 2019 |
Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y, Zhang J. Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone. Journal of Cancer Research and Clinical Oncology. PMID 31172267 DOI: 10.1007/S00432-019-02950-Y |
0.527 |
|
| 2019 |
Ahmed AA, Robinson T, Palande M, Escara-Wilke J, Dai J, Keller ET. Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression. Journal of Cellular Biochemistry. PMID 31099068 DOI: 10.1002/Jcb.28954 |
0.464 |
|
| 2019 |
Wang W, Yang X, Dai J, Lu Y, Zhang J, Keller ET. Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion. Oncogene. PMID 30755731 DOI: 10.1038/S41388-019-0736-3 |
0.565 |
|
| 2019 |
Lorenzatti Hiles G, Cates AL, El-Sawy L, Day KC, Broses LJ, Han AL, Briggs HL, Emamdjomeh A, Chou A, Abel EV, Liebert M, Palmbos PL, Udager AM, Keller ET, Day ML. A surgical orthotopic approach for studying the invasive progression of human bladder cancer. Nature Protocols. PMID 30683938 DOI: 10.1038/S41596-018-0112-8 |
0.366 |
|
| 2019 |
Chang M, Huang X, Lu S, Zhang W, Liang W, Keller E, Lu X, Zhang J. Abstract 2784: Driver genes network promotes mesenchymal to epithelial transition and organ-specific metastasis Cancer Research. 79: 2784-2784. DOI: 10.1158/1538-7445.Am2019-2784 |
0.444 |
|
| 2018 |
Tong H, Zou C, Qin S, Meng J, Keller ET, Zhang J, Lu Y. Prostate cancer tends to metastasize in the bone-mimicking microenvironment via activating NF-κB signaling. Journal of Biomedical Research. PMID 30190448 DOI: 10.7555/Jbr.32.20180035 |
0.547 |
|
| 2018 |
Miller DR, Tzeng CC, Farmer T, Keller ET, Caplan S, Chen YS, Chen YL, Lin MF. Novel CIL-102 Derivatives as Potential Therapeutic Agents for Docetaxel-Resistant Prostate Cancer. Cancer Letters. PMID 30077739 DOI: 10.1016/J.Canlet.2018.07.039 |
0.47 |
|
| 2018 |
Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, Lazo de la Vega L, Palapattu G, Veeneman B, El-Sawy L, Sadis SE, Morgan TM, Montgomery JS, Weizer AZ, Day KC, ... ... Keller ET, et al. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. European Urology. PMID 30033047 DOI: 10.1016/J.Eururo.2018.06.047 |
0.348 |
|
| 2018 |
Machioka K, Izumi K, Kadono Y, Iwamoto H, Naito R, Makino T, Kadomoto S, Natsagdorj A, Keller ET, Zhang J, Mizokami A. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget. 9: 16185-16196. PMID 29662635 DOI: 10.18632/Oncotarget.24609 |
0.384 |
|
| 2018 |
Takezawa Y, Izumi K, Machioka K, Iwamoto H, Naito R, Makino T, Kadomoto S, Natsagdorj A, Kadono Y, Keller ET, Zhang J, Mizokami A. Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. Anticancer Research. 38: 2045-2055. PMID 29599322 DOI: 10.21873/anticanres.12444 |
0.373 |
|
| 2018 |
Shi J, Wang L, Zou C, Xia Y, Qin S, Keller E, Mizokami A, Zhang J, Lu Y. Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway. Oncotarget. 9: 9206-9218. PMID 29507684 DOI: 10.18632/Oncotarget.24104 |
0.529 |
|
| 2018 |
Meng J, Liang W, Tong H, Keller ET, Zhang J, Lu Y. Abstract 996: Host-derived MCP-1 dictates prostate cancer skeletal metastasis in vivo Tumor Biology. DOI: 10.1158/1538-7445.Am2018-996 |
0.481 |
|
| 2018 |
Osawa T, Robinson S, Leung B, Dai J, Takayama S, Keller ET. MP70-06 MICRO- AND MACRO-FLUIDIC MODELS OF PROSTATE CANCER METASTASIS Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2250 |
0.482 |
|
| 2017 |
Roca H, Jones JD, Purica MC, Weidner S, Koh AJ, Kuo R, Wilkinson JE, Wang Y, Daignault-Newton S, Pienta KJ, Morgan TM, Keller ET, Nör JE, Shea LD, McCauley LK. Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. The Journal of Clinical Investigation. PMID 29202471 DOI: 10.1172/Jci92466 |
0.558 |
|
| 2017 |
Park SH, Keller ET, Shiozawa Y. Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcified Tissue International. PMID 29094177 DOI: 10.1007/S00223-017-0350-8 |
0.53 |
|
| 2017 |
Lin E, Rivera-Báez L, Fouladdel S, Yoon HJ, Guthrie S, Wieger J, Deol Y, Keller E, Sahai V, Simeone DM, Burness ML, Azizi E, Wicha MS, Nagrath S. High-Throughput Microfluidic Labyrinth for the Label-free Isolation of Circulating Tumor Cells. Cell Systems. PMID 28941584 DOI: 10.1016/J.Cels.2017.08.012 |
0.363 |
|
| 2017 |
Farhat A, Jiang D, Cui D, Keller ET, Jackson TL. An Integrative Model of Prostate Cancer Interaction with the Bone Microenvironment. Mathematical Biosciences. PMID 28919575 DOI: 10.1016/J.Mbs.2017.09.005 |
0.423 |
|
| 2017 |
Guo Y, Zhang Z, Wei H, Wang J, Lv J, Zhang K, Keller ET, Yao Z, Wang Q. Cytotoxic Necrotizing Factor 1 Promotes Prostate Cancer Progression Through Activating the Cdc42-PAK1 Axis. The Journal of Pathology. PMID 28707808 DOI: 10.1002/Path.4940 |
0.494 |
|
| 2017 |
Han AL, Veeneman BA, El-Sawy L, Day KC, Day ML, Tomlins SA, Keller ET. Fibulin-3 promotes muscle-invasive bladder cancer. Oncogene. PMID 28504717 DOI: 10.1038/Onc.2017.149 |
0.402 |
|
| 2017 |
Wang W, Wang L, Mizokami A, Shi J, Zou C, Dai J, Keller ET, Lu Y, Zhang J. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer. 36: 35. PMID 28356132 DOI: 10.1186/S40880-017-0203-X |
0.465 |
|
| 2017 |
Jiang Y, Dai J, Yao Z, Shelley G, Keller ET. Abituzumab Targeting of AlphaV-class Integrins Inhibits Prostate Cancer Progression. Molecular Cancer Research : McR. PMID 28314844 DOI: 10.1158/1541-7786.Mcr-16-0447 |
0.482 |
|
| 2017 |
Dai J, Lu Y, Roca H, Keller JM, Zhang J, McCauley LK, Keller ET. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer. 36: 29. PMID 28292326 DOI: 10.1186/S40880-017-0198-3 |
0.477 |
|
| 2017 |
Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D, Deng J, Zhang J. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Scientific Reports. 7: 41656. PMID 28134352 DOI: 10.1038/Srep41656 |
0.486 |
|
| 2017 |
Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian CN, Zhang J, Lu Y. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer. 36: 17. PMID 28126011 DOI: 10.1186/S40880-017-0184-9 |
0.361 |
|
| 2017 |
Zhang M, Osisami M, Dai J, Keller JM, Escara-Wilke J, Mizokami A, Keller ET. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. Molecular Cancer Research : McR. PMID 28087740 DOI: 10.1158/1541-7786.Mcr-16-0392 |
0.441 |
|
| 2017 |
Mizokami A, Machioka K, Izumi K, Aerken M, Natsagdorji A, Kadono Y, Takezawa Y, Iwamoto H, Keller ET. Abstract 85: Establishment of cabazitaxel-resistant prostate cancer cell lines Cancer Research. 77: 85-85. DOI: 10.1158/1538-7445.Am2017-85 |
0.438 |
|
| 2017 |
Qin S, Song Q, Dai J, Tong H, Keller E, Zhang J, Lu Y. Abstract 4939: Activation of GSK3β/β-catenin pathway promotes organ-specific metastasis in prostate cancer Cancer Research. 77: 4939-4939. DOI: 10.1158/1538-7445.Am2017-4939 |
0.438 |
|
| 2017 |
Liu Y, Xie L, Li J, Mizokami A, Keller ET, Lu Y, Zhang J. Abstract 1462: Exosome-derived miR-429 contributes to prostate cancer chemoresistance Cancer Research. 77: 1462-1462. DOI: 10.1158/1538-7445.Am2017-1462 |
0.42 |
|
| 2017 |
Xu G, Cheng Q, Huang S, Qin M, Hopkins T, Lee CH, Kopelman R, Chao W, Keller ET, Wu D, Wang X. Photoacoustic physio-chemical analysis for prostate cancer diagnosis (Conference Presentation) Proceedings of Spie. 10064: 1006429. DOI: 10.1117/12.2252262 |
0.448 |
|
| 2016 |
Mandair GS, Han AL, Keller ET, Morris MD. Raman microscopy of bladder cancer cells expressing green fluorescent protein. Journal of Biomedical Optics. 21: 115001. PMID 27805248 DOI: 10.1117/1.Jbo.21.11.115001 |
0.33 |
|
| 2016 |
Day KC, Lorenzatti Hiles G, Kozminsky M, Dawsey SJ, Paul A, Broses LJ, Shah R, Kunju LP, Hall C, Palanisamy N, Daignault-Newton S, El-Sawy L, Wilson SJ, Chou A, Ignatoski KM, ... Keller ET, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone. Cancer Research. PMID 27793843 DOI: 10.1158/0008-5472.Can-16-1656 |
0.551 |
|
| 2016 |
Osawa T, Wittmann D, Jimbo M, Keller ET, Namiki S, Abe T, Shinohara N, Skolarus TA. Providing prostate cancer survivorship care in Japan: Implications from the USA care model. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 27624609 DOI: 10.1111/Iju.13186 |
0.394 |
|
| 2016 |
Chen Q, Qin S, Liu Y, Hong M, Qian CN, Keller ET, Zhang J, Lu Y. IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget. PMID 27623076 DOI: 10.18632/Oncotarget.11886 |
0.35 |
|
| 2016 |
Tang Y, Feinberg T, Keller ET, Li XY, Weiss SJ. Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation. Nature Cell Biology. PMID 27479603 DOI: 10.1038/Ncb3394 |
0.345 |
|
| 2016 |
Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN. Phase II studies of two different schedules of dasatinib in ***bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Research and Treatment. PMID 27475087 DOI: 10.1007/S10549-016-3911-Z |
0.401 |
|
| 2016 |
Li J, Yang X, Guan H, Mizokami A, Keller ET, Xu X, Liu X, Tan J, Hu L, Lu Y, Zhang J. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology. PMID 27278879 DOI: 10.3892/Ijo.2016.3560 |
0.304 |
|
| 2016 |
Yang Y, Lu Y, Wang L, Mizokami A, Keller ET, Zhang J, Fu J. Skp2 is associated with paclitaxel resistance in prostate cancer cells. Oncology Reports. PMID 27175797 DOI: 10.3892/Or.2016.4809 |
0.505 |
|
| 2016 |
Yang T, Yao H, He G, Song L, Liu N, Wang Y, Yang Y, Keller ET, Deng X. Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis. Journal of Cancer. 7: 192-9. PMID 26819643 DOI: 10.7150/Jca.13414 |
0.386 |
|
| 2016 |
Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, et al. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia (New York, N.Y.). 18: 1-9. PMID 26806347 DOI: 10.1016/J.Neo.2015.11.009 |
0.438 |
|
| 2016 |
Han AL, Veeneman B, Tomlins SA, Keller ET. Abstract 692: Identifying genes that regulate bladder cancer progression and invasion Cancer Research. 76: 692-692. DOI: 10.1158/1538-7445.Am2016-692 |
0.394 |
|
| 2016 |
Lin E, Rivera L, Fouladdel S, Yoon HJ, Guthrie S, Weiner J, Deol YS, Keller E, Sahai V, Simeone DM, Burness ML, Azizi E, Wicha MS, Nagrath S. Abstract 3307: Label-free high throughput microfluidic device for the isolation and single cell multiplex gene expression analysis of circulating tumor cells from breast cancer patients Cancer Research. 76: 3307-3307. DOI: 10.1158/1538-7445.Am2016-3307 |
0.372 |
|
| 2016 |
Dai J, Lu Y, Zhang J, Keller E. Abstract 1567: Prostate cancer-derived exosomes alter the metabolic microenvironment of bone marrow pre-metastatic niche through PKM2 to promote bone metastasis Cancer Research. 76: 1567-1567. DOI: 10.1158/1538-7445.Am2016-1567 |
0.548 |
|
| 2015 |
Wang JQ, DeChalus A, Chatterjee DN, Keller ET, Mizokami A, Camussi G, Mendelsohn AR, Renzulli Ii JF, Quesenberry PJ, Chatterjee D. Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer. Critical Reviews in Oncogenesis. 20: 407-17. PMID 27279238 DOI: 10.1615/CritRevOncog.v20.i5-6.120 |
0.373 |
|
| 2015 |
Guo H, Zhou X, Lu Y, Xie L, Chen Q, Keller ET, Liu Q, Zhou Q, Zhang J. Translational progress on tumor biomarkers. Thoracic Cancer. 6: 665-71. PMID 26557902 DOI: 10.1111/1759-7714.12294 |
0.323 |
|
| 2015 |
He S, Lu Y, Liu X, Huang X, Keller ET, Qian CN, Zhang J. Wnt3a: functions and implications in cancer. Chinese Journal of Cancer. 34: 50. PMID 26369691 DOI: 10.1186/S40880-015-0052-4 |
0.401 |
|
| 2015 |
Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26202948 DOI: 10.1158/1078-0432.Ccr-15-0242 |
0.505 |
|
| 2015 |
Ge C, Zhao G, Li Y, Li H, Zhao X, Pannone G, Bufo P, Santoro A, Sanguedolce F, Tortorella S, Mattoni M, Papagerakis S, Keller ET, Franceschi RT. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene. PMID 25867060 DOI: 10.1038/Onc.2015.91 |
0.494 |
|
| 2015 |
Sottnik JL, Dai J, Zhang H, Campbell B, Keller ET. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Research. 75: 2151-8. PMID 25855383 DOI: 10.1158/0008-5472.Can-14-2493 |
0.508 |
|
| 2015 |
Escara-Wilke J, Keller JM, Ignatoski KM, Dai J, Shelley G, Mizokami A, Zhang J, Yeung ML, Yeung KC, Keller ET. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer. The Prostate. 75: 292-302. PMID 25327941 DOI: 10.1002/Pros.22915 |
0.484 |
|
| 2015 |
Jung Y, Wang J, Lee E, McGee S, Berry JE, Yumoto K, Dai J, Keller ET, Shiozawa Y, Taichman RS. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Molecular Cancer Research : McR. 13: 197-207. PMID 25139998 DOI: 10.1158/1541-7786.Mcr-14-0118 |
0.548 |
|
| 2015 |
Wang JQ, Dechalus A, Chatterjee DN, Keller ET, Mizokami A, Camussi G, Mendelsohn AR, Renzulli JF, Quesenberry PJ, Chatterjee D. Extracellular vesicle-mediated reversal of paclitaxel resistance in prostate cancer Critical Reviews in Oncogenesis. 20: 407-418. DOI: 10.1615/CritRevOncog.v20.i5-6.120 |
0.373 |
|
| 2014 |
Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J. Targeting the Notch signaling pathway in cancer therapeutics. Thoracic Cancer. 5: 473-86. PMID 26767041 DOI: 10.1111/1759-7714.12143 |
0.349 |
|
| 2014 |
Lamiman K, Keller JM, Mizokami A, Zhang J, Keller ET. Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types. Critical Reviews in Oncogenesis. 19: 455-68. PMID 25597355 DOI: 10.1615/CritRevOncog.2014011987 |
0.349 |
|
| 2014 |
Soki FN, Koh AJ, Jones JD, Kim YW, Dai J, Keller ET, Pienta KJ, Atabai K, Roca H, McCauley LK. Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. The Journal of Biological Chemistry. 289: 24560-72. PMID 25006249 DOI: 10.1074/Jbc.M114.571620 |
0.408 |
|
| 2014 |
Kim J, Mizokami A, Shin M, Izumi K, Konaka H, Kadono Y, Kitagawa Y, Keller ET, Zhang J, Namiki M. SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation. Anticancer Research. 34: 2821-31. PMID 24922645 |
0.38 |
|
| 2014 |
Deng X, He G, Liu J, Luo F, Peng X, Tang S, Gao Z, Lin Q, Keller JM, Yang T, Keller ET. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treatment Reviews. 40: 730-8. PMID 24767837 DOI: 10.1016/J.Ctrv.2014.04.003 |
0.481 |
|
| 2014 |
Sottnik JL, Campbell B, Mehra R, Behbahani-Nejad O, Hall CL, Keller ET. Osteocytes serve as a progenitor cell of osteosarcoma. Journal of Cellular Biochemistry. 115: 1420-9. PMID 24700678 DOI: 10.1002/Jcb.24793 |
0.397 |
|
| 2014 |
Dai J, Zhang H, Karatsinides A, Keller JM, Kozloff KM, Aftab DT, Schimmoller F, Keller ET. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 617-30. PMID 24097861 DOI: 10.1158/1078-0432.Ccr-13-0839 |
0.514 |
|
| 2014 |
Zhang H, Yu C, Dai J, Keller JM, Hua A, Sottnik JL, Shelley G, Hall CL, Park SI, Yao Z, Zhang J, McCauley LK, Keller ET. Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer. Oncogene. 33: 2464-77. PMID 23752183 DOI: 10.1038/Onc.2013.203 |
0.513 |
|
| 2014 |
Simmons J, Elshafae S, Keller E, McCauley L, Rosol T. Review of Animal Models of Prostate Cancer Bone Metastasis Veterinary Sciences. 1: 16-39. DOI: 10.3390/Vetsci1010016 |
0.522 |
|
| 2014 |
Nadeem O, Mega AE, Keller ET, Renzulli JF, Quesenberry PJ, Chatterjee D. Extracellular vesicle-mediated reversal of taxane resistance and the malignant phenotype in prostate cancer. Journal of Clinical Oncology. 32: e16028-e16028. DOI: 10.1200/Jco.2014.32.15_Suppl.E16028 |
0.474 |
|
| 2014 |
Grivas P, Daignault S, Cooney KA, Jacobson J, Yablon C, Ross BD, Chenevert TL, Hoff B, Rehemtulla A, Keller ET, Mehra R, Shelley G, Alva AS, Hussain M, Smith DC. Cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219): Evaluation of bone metastasis microenvironment. Journal of Clinical Oncology. 32: e16015-e16015. DOI: 10.1200/Jco.2014.32.15_Suppl.E16015 |
0.503 |
|
| 2014 |
Wang W, Lu Y, Zhou X, Mizokami A, Keller E, Zhang J. Abstract 772: CCL2 regulates EMT-mediated chemo-resistance in prostate cancer Cancer Research. 74: 772-772. DOI: 10.1158/1538-7445.Am2014-772 |
0.518 |
|
| 2014 |
Mizokami A, Ofude M, Kumaki M, Izumi K, Konaka H, Kadono Y, Shin M, Zhang J, Keller ET, Namiki M. Abstract 617: Repression of cell proliferation and androgen receptor activity by 2’-hydroxyflavanone in prostate cancer cells Cancer Research. 74: 617-617. DOI: 10.1158/1538-7445.Am2014-617 |
0.517 |
|
| 2014 |
Li C, Guo H, Lu Y, Dai J, Keller E, Zhang J. Abstract 3198: Extract from Scutellaria baicalensis Georgi inhibits prostate cancer growth in bone Cancer Research. 74: 3198-3198. DOI: 10.1158/1538-7445.Am2014-3198 |
0.494 |
|
| 2014 |
Shi J, Xia Y, Song Q, Zhou X, Mizokami A, Keller E, Zhang J, Lu Y. Abstract 1: Interaction of prostate cancer cells with tumor microenvironment promotes EMT and DTCs activation Cancer Research. 74: 1-1. DOI: 10.1158/1538-7445.Am2014-1 |
0.525 |
|
| 2014 |
Keller JM, Schade GR, Ives K, Cheng X, Rosol TJ, Piert M, Siddiqui J, Roberts WW, Keller ET. Erratum: A novel canine model for prostate cancer (Prostate (2013) 73:9 (952-959)) The Prostate. 74. DOI: 10.1002/Pros.22856 |
0.465 |
|
| 2013 |
Karatsinides A, Day KC, Kunju P, Paul A, Shakir N, Keller ET, Hussain M, Day ML. Evaluation of a novel irreversible pan-HER inhibitor in bladder cancer models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 253. PMID 28136908 DOI: 10.1200/Jco.2013.31.6_Suppl.253 |
0.392 |
|
| 2013 |
Osisami M, Keller ET. Mechanisms of Metastatic Tumor Dormancy. Journal of Clinical Medicine. 2: 136-50. PMID 26237067 DOI: 10.3390/Jcm2030136 |
0.397 |
|
| 2013 |
Grivas PD, Keller ET. Prostate cancer: radium-223: a new treatment option for bone-metastatic CRPC. Nature Reviews. Urology. 10: 630-1. PMID 24126730 DOI: 10.1038/Nrurol.2013.232 |
0.491 |
|
| 2013 |
Ofude M, Mizokami A, Kumaki M, Izumi K, Konaka H, Kadono Y, Kitagawa Y, Shin M, Zhang J, Keller ET, Namiki M. Repression of cell proliferation and androgen receptor activity in prostate cancer cells by 2'-hydroxyflavanone. Anticancer Research. 33: 4453-61. PMID 24123015 |
0.413 |
|
| 2013 |
Jiang Y, Dai J, Zhang H, Sottnik JL, Keller JM, Escott KJ, Sanganee HJ, Yao Z, McCauley LK, Keller ET. Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone. Molecular Cancer Research : McR. 11: 1597-610. PMID 24088787 DOI: 10.1158/1541-7786.Mcr-13-0332-T |
0.571 |
|
| 2013 |
Shiozawa Y, Taichman RS, Keller ET. Detection and isolation of human disseminated tumor cells in the murine bone marrow stem cell niche. Methods in Molecular Biology (Clifton, N.J.). 1035: 207-15. PMID 23959994 DOI: 10.1007/978-1-62703-508-8_18 |
0.413 |
|
| 2013 |
Osisami M, Keller ET. SPDEF: a molecular switch for E-cadherin expression that promotes prostate cancer metastasis. Asian Journal of Andrology. 15: 584-5. PMID 23708459 DOI: 10.1038/Aja.2013.64 |
0.511 |
|
| 2013 |
Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, Wang J, Jin T, Zhang H, Dai J, Krebsbach PH, ... Keller ET, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications. 4: 1795. PMID 23653207 DOI: 10.1038/Ncomms2766 |
0.434 |
|
| 2013 |
Shin M, Mizokami A, Kim J, Ofude M, Konaka H, Kadono Y, Kitagawa Y, Miwa S, Kumaki M, Keller ET, Namiki M. Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1. The Prostate. 73: 1159-70. PMID 23532895 DOI: 10.1002/Pros.22664 |
0.501 |
|
| 2013 |
Keller JM, Schade GR, Ives K, Cheng X, Rosol TJ, Piert M, Siddiqui J, Roberts WW, Keller ET. A novel canine model for prostate cancer. The Prostate. 73: 952-9. PMID 23335024 DOI: 10.1002/Pros.22642 |
0.471 |
|
| 2013 |
Sottnik JL, Daignault-Newton S, Zhang X, Morrissey C, Hussain MH, Keller ET, Hall CL. Integrin alpha2beta 1 (α2β1) promotes prostate cancer skeletal metastasis. Clinical & Experimental Metastasis. 30: 569-78. PMID 23242739 DOI: 10.1007/S10585-012-9561-6 |
0.536 |
|
| 2013 |
Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer Cancer and Metastasis Reviews. 32: 303-315. PMID 23114846 DOI: 10.1007/S10555-012-9415-3 |
0.435 |
|
| 2013 |
Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Current Molecular Medicine. 13: 626-39. PMID 23061677 DOI: 10.2174/1566524011313040012 |
0.546 |
|
| 2013 |
Grivas P, Daignault S, Cooney KA, Jacobson J, Yablon C, Ross BD, Chenevert TL, Galbán CJ, Rehemtulla A, Keller ET, Kunju P, Mehra R, Escara-Wilke J, Shelley G, Pienta KJ, et al. A phase II trial of cabozantinib (Cabo) in patients (pts) with castrate-resistant prostate cancer (CRPC) metastatic to bone (NCT01428219). Journal of Clinical Oncology. 31: TPS5094-TPS5094. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps5094 |
0.445 |
|
| 2013 |
Sottnik JL, Daignault-Newton S, Zhang X, Colm M, Hussain MH, Keller ET, Hall CL. Abstract B49: Integrin alpha2beta1 (α2β1) promotes prostate cancer skeletal metastasis Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B49 |
0.547 |
|
| 2013 |
Yang X, Xiao Z, Wang J, Lu Y, Xu Y, Huang X, Mizokami A, Keller ET, Zhang J. Abstract 3945: IKK-Epsilon, a novel factor identified by proteomics, contributes to prostate cancer cell-induced osteoclast activityin vitro. Cancer Research. 73: 3945-3945. DOI: 10.1158/1538-7445.Am2013-3945 |
0.529 |
|
| 2012 |
Sottnik JL, Hall CL, Zhang J, Keller ET. Wnt and Wnt inhibitors in bone metastasis. Bonekey Reports. 1: 101. PMID 23951488 DOI: 10.1038/Bonekey.2012.101 |
0.435 |
|
| 2012 |
Zhang H, Wu J, Keller JM, Yeung K, Keller ET, Fu Z. Transcriptional regulation of RKIP expression by androgen in prostate cells. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 30: 1340-50. PMID 23095933 DOI: 10.1159/000343323 |
0.625 |
|
| 2012 |
Schade GR, Keller J, Ives K, Cheng X, Rosol TJ, Keller E, Roberts WW. Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. The Journal of Urology. 188: 1957-64. PMID 22999534 DOI: 10.1016/J.Juro.2012.07.006 |
0.469 |
|
| 2012 |
Yu C, Shiozawa Y, Taichman RS, McCauley LK, Pienta K, Keller E. Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Critical Reviews in Eukaryotic Gene Expression. 22: 131-48. PMID 22856431 DOI: 10.1615/Critreveukargeneexpr.V22.I2.50 |
0.434 |
|
| 2012 |
Jung Y, Shiozawa Y, Wang J, McGregor N, Dai J, Park SI, Berry JE, Havens AM, Joseph J, Kim JK, Patel L, Carmeliet P, Daignault S, Keller ET, McCauley LK, et al. Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia (New York, N.Y.). 14: 429-39. PMID 22745589 DOI: 10.1596/Neo.111740 |
0.492 |
|
| 2012 |
Zhao E, Wang L, Dai J, Kryczek I, Wei S, Vatan L, Altuwaijri S, Sparwasser T, Wang G, Keller ET, Zou W. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology. 1: 152-161. PMID 22720236 DOI: 10.4161/Onci.1.2.18480 |
0.518 |
|
| 2012 |
Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Reviews. 31: 615-20. PMID 22684368 DOI: 10.1007/S10555-012-9365-9 |
0.455 |
|
| 2012 |
Shima T, Mizokami A, Miyagi T, Kawai K, Izumi K, Kumaki M, Ofude M, Zhang J, Keller ET, Namiki M. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer. The Prostate. 72: 1789-801. PMID 22549914 DOI: 10.1002/Pros.22533 |
0.481 |
|
| 2012 |
Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Research. 72: 3091-104. PMID 22505648 DOI: 10.1158/0008-5472.Can-11-3546 |
0.445 |
|
| 2012 |
Joseph J, Shiozawa Y, Jung Y, Kim JK, Pedersen E, Mishra A, Zalucha JL, Wang J, Keller ET, Pienta KJ, Taichman RS. Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Molecular Cancer Research : McR. 10: 282-92. PMID 22241219 DOI: 10.1158/1541-7786.Mcr-11-0404 |
0.492 |
|
| 2012 |
Mizokami A, Shima T, Miyagi T, Kawai K, Izumi K, Kumaki M, Jian Z, Keller ET, Namiki M. Abstract 944: Down-regulation of CAMKK2 by androgen deprivation induces castration-resistant prostate cancer Cancer Research. 72: 944-944. DOI: 10.1158/1538-7445.Am2012-944 |
0.473 |
|
| 2012 |
Zou C, Lu Y, Mizokami A, Keller ET, Pienta KJ, Zhang J. Abstract 841: CCL2 and interleukin-6 regulate EMT-mediated chemo-resistance in prostate cancer Cancer Research. 72: 841-841. DOI: 10.1158/1538-7445.Am2012-841 |
0.498 |
|
| 2012 |
Sottnik JL, Hall C, Karatsinides A, Keller AL, Ettenberg SA, Keller ET. Abstract 3794: Inhibition of prostate cancer bone metastases by the dickkopf-1 neutralizing antibody BHQ880 Cancer Research. 72: 3794-3794. DOI: 10.1158/1538-7445.Am2012-3794 |
0.463 |
|
| 2012 |
Dai J, Zhang H, Karatsinides A, Aftab D, Schimmoller F, Keller ET. Abstract 2851: Cabozantinib (XL184) inhibits prostate tumor growth and bone lesion development Cancer Research. 72: 2851-2851. DOI: 10.1158/1538-7445.Am2012-2851 |
0.55 |
|
| 2012 |
Esmonde-White KA, Sottnik J, Morris M, Keller E. Raman spectroscopy of bone metastasis Progress in Biomedical Optics and Imaging - Proceedings of Spie. 8207. DOI: 10.1117/12.909327 |
0.424 |
|
| 2012 |
Schade GR, Keller J, Ives K, Cheng X, Rosol TJ, Keller ET, Roberts WW. Prostate Cancer: Basic Research IVModerated Poster794 HISTOTRIPSY FOCAL ABLATION OF IMPLANTED PROSTATE TUMOR IN AN ACE-1 CANINE CANCER MODEL The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.882 |
0.48 |
|
| 2011 |
Keller ET. Role of Raf Kinase Inhibitor Protein in Pathophysiology of Prostate Cancer. Forum On Immunopathological Diseases and Therapeutics. 2: 89-94. PMID 21984962 DOI: 10.1615/Forumimmundisther.V2.I1 |
0.537 |
|
| 2011 |
McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, Buckanovich RJ. Human ovarian carcinoma–associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. The Journal of Clinical Investigation. 121: 3206-19. PMID 21737876 DOI: 10.1172/Jci45273 |
0.382 |
|
| 2011 |
Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa Tumor Microenvironment. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 4: 283-97. PMID 21728070 DOI: 10.1007/S12307-011-0073-8 |
0.391 |
|
| 2011 |
Keller ET. Prostate cancer cells metastasize to the hematopoietic stem cell niche in bone. Asian Journal of Andrology. 13: 622-3. PMID 21623388 DOI: 10.1038/aja.2011.50 |
0.417 |
|
| 2011 |
Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Dakin-Haché K, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3112-22. PMID 21364031 DOI: 10.1158/1078-0432.Ccr-10-1264 |
0.476 |
|
| 2011 |
Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, Werbeck JL, Simmons JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, et al. Development of a brain metastatic canine prostate cancer cell line. The Prostate. 71: 1251-63. PMID 21321976 DOI: 10.1002/Pros.21341 |
0.494 |
|
| 2011 |
Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X, Keller ET. ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo (Athens, Greece). 25: 69-76. PMID 21282737 |
0.313 |
|
| 2011 |
Ramsay AK, McCracken SR, Soofi M, Fleming J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, Nuttall RK, Seywright M, Marquez R, Keller E, Leung HY. ERK5 signalling in prostate cancer promotes an invasive phenotype. British Journal of Cancer. 104: 664-72. PMID 21266977 DOI: 10.1038/Sj.Bjc.6606062 |
0.443 |
|
| 2011 |
Keller ET, Li LY. The first Tianjin, China forum on tumor microenvironment. Cancer Research. 71: 310-3. PMID 21224351 DOI: 10.1158/0008-5472.Can-10-2930 |
0.427 |
|
| 2011 |
Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Werbeck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. The Prostate. 71: 615-25. PMID 20957670 DOI: 10.1002/Pros.21277 |
0.556 |
|
| 2011 |
Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, ... Keller ET, et al. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Investigational New Drugs. 29: 1432-40. PMID 20336348 DOI: 10.1007/s10637-010-9420-8 |
0.416 |
|
| 2011 |
Lu Y, Chen Q, Qi W, Hong M, Mizokami A, Keller E, Zhang J. Abstract LB-374: IGFBP-6, a novel prognostic biomarker in nasopharyngeal carcinoma (NPC) patients Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-374 |
0.445 |
|
| 2011 |
Hall* C, Zhang H, Baile S, Kuhstoss S, Keller E. Inhibition of Dickkopf-1 (DKK-1) delays prostate cancer growth in vivo through induction of P21CIP-1 Bone. 48: S43-S44. DOI: 10.1016/J.Bone.2010.10.123 |
0.474 |
|
| 2011 |
Bradley DA, Daignault S, Ryan CJ, DiPaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, ... Keller ET, et al. Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8) Investigational New Drugs. 29: 1517-1518. DOI: 10.1007/S10637-010-9502-7 |
0.434 |
|
| 2010 |
Hall CL, Zhang H, Baile S, Ljungman M, Kuhstoss S, Keller ET. p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Research. 70: 9916-26. PMID 21098705 DOI: 10.1158/0008-5472.Can-10-0440 |
0.541 |
|
| 2010 |
Dai J, Lu Y, Yu C, Keller JM, Mizokami A, Zhang J, Keller ET. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Research. 70: 5014-23. PMID 20501834 DOI: 10.1158/0008-5472.Can-10-0100 |
0.467 |
|
| 2010 |
Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 29: 811-21. PMID 19915614 DOI: 10.1038/Onc.2009.389 |
0.592 |
|
| 2010 |
Li Y, Mizokami A, Izumi K, Narimoto K, Shima T, Zhang J, Dai J, Keller ET, Namiki M. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer. The Prostate. 70: 48-60. PMID 19725034 DOI: 10.1002/Pros.21037 |
0.475 |
|
| 2010 |
Ramsay A, McCracken S, Morland R, Fleming J, Machesky L, Yu X, Edwards D, Nuttall R, Seywright M, Keller E, Leung H. 381 ABERRANT EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASE 5 (ERK5) SIGNALLING PROMOTES CELLULAR MOTILITY AND INVASION IN PROSTATE CARCINOGENESIS Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.449 |
0.389 |
|
| 2010 |
Keller ET, Hall CL. Pathophysiology of prostate cancer bone metastasis Drug Management of Prostate Cancer. 245-254. DOI: 10.1007/978-1-60327-829-4_22 |
0.444 |
|
| 2009 |
Jung Y, Shiozawa Y, Wang J, Wang J, Wang Z, Pedersen EA, Lee CH, Hall CL, Hogg PJ, Krebsbach PH, Keller ET, Taichman RS. Expression of PGK1 by prostate cancer cells induces bone formation. Molecular Cancer Research : McR. 7: 1595-604. PMID 19825988 DOI: 10.1158/1541-7786.Mcr-09-0072 |
0.517 |
|
| 2009 |
Mizokami A, Koh E, Izumi K, Narimoto K, Takeda M, Honma S, Dai J, Keller ET, Namiki M. Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocrine-Related Cancer. 16: 1139-55. PMID 19608712 DOI: 10.1677/Erc-09-0070 |
0.482 |
|
| 2009 |
Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. The Prostate. 69: 1222-34. PMID 19434660 DOI: 10.1002/Pros.20975 |
0.52 |
|
| 2009 |
Lester PA, Keller ET. The comparative biology of skeletal metastasis. Veterinary and Comparative Oncology. 1: 131-9. PMID 19379312 DOI: 10.1111/J.1476-5829.2003.00023.X |
0.398 |
|
| 2009 |
DeHaan AM, Wolters NM, Keller ET, Ignatoski KM. EGFR ligand switch in late stage prostate cancer contributes to changes in cell signaling and bone remodeling. The Prostate. 69: 528-37. PMID 19143022 DOI: 10.1002/Pros.20903 |
0.496 |
|
| 2009 |
Ignatoski KM, Friedman J, Escara-Wilke J, Zhang X, Daignault S, Dunn RL, Smith DC, Keller ET. Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 29: 105-12. PMID 19014338 DOI: 10.1089/Jir.2008.0024 |
0.448 |
|
| 2008 |
Bradley DA, Daignault S, Ryan C, DiPaola RP, Smith DC, Mathew P, Gross M, Chen AP, Keller ET, Hussain MH. Cilengitide in asymptomatic metastatic androgen independent prostate cancer (AIPC) patients (pts): A randomized phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5144. PMID 27948180 DOI: 10.1200/Jco.2008.26.15_Suppl.5144 |
0.494 |
|
| 2008 |
Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, Hu CD. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Research. 68: 9663-70. PMID 19047143 DOI: 10.1158/0008-5472.Can-08-2229 |
0.502 |
|
| 2008 |
Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 72: 153-60. PMID 18722266 DOI: 10.1016/J.Ijrobp.2008.04.072 |
0.479 |
|
| 2008 |
Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, van Golen KL. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia (New York, N.Y.). 10: 797-803. PMID 18670640 DOI: 10.1593/Neo.08380 |
0.478 |
|
| 2008 |
Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Research. 68: 5785-94. PMID 18632632 DOI: 10.1158/0008-5472.Can-07-6541 |
0.493 |
|
| 2008 |
Hall CL, Daignault SD, Shah RB, Pienta KJ, Keller ET. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. The Prostate. 68: 1396-404. PMID 18561248 DOI: 10.1002/Pros.20805 |
0.459 |
|
| 2008 |
Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. International Journal of Cancer. Journal International Du Cancer. 123: 1034-42. PMID 18546262 DOI: 10.1002/Ijc.23625 |
0.409 |
|
| 2008 |
Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, McCauley LK, Loberg RD, Pienta KJ, Taichman RS. An in vivo mouse model for human prostate cancer metastasis. Neoplasia (New York, N.Y.). 10: 371-80. PMID 18392141 DOI: 10.1593/Neo.08154 |
0.473 |
|
| 2008 |
Ignatoski KM, Escara-Wilke JF, Dai JL, Lui A, Dougall W, Daignault S, Yao Z, Zhang J, Day ML, Sargent EE, Keller ET. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model. The Prostate. 68: 820-9. PMID 18324676 DOI: 10.1002/Pros.20744 |
0.531 |
|
| 2008 |
Pettway GJ, Meganck JA, Koh AJ, Keller ET, Goldstein SA, McCauley LK. Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone. 42: 806-18. PMID 18234576 DOI: 10.1016/J.Bone.2007.11.017 |
0.382 |
|
| 2008 |
Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. The Prostate. 68: 92-104. PMID 18008334 DOI: 10.1002/Pros.20678 |
0.538 |
|
| 2008 |
Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene. 27: 2243-8. PMID 17952120 DOI: 10.1038/Sj.Onc.1210860 |
0.489 |
|
| 2007 |
Keller ET, Dai J, Escara-Wilke J, Hall CL, Ignatoski K, Taichman RS, Keller J. New trends in the treatment of bone metastasis. Journal of Cellular Biochemistry. 102: 1095-102. PMID 17955492 DOI: 10.1002/Jcb.21540 |
0.38 |
|
| 2007 |
Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruszkewicz AM, Gomez J, Mohla S, Getzenberg RH. Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Research. 67: 9613-5. PMID 17928375 DOI: 10.1158/0008-5472.Can-07-1529 |
0.471 |
|
| 2007 |
Takeda M, Mizokami A, Mamiya K, Li YQ, Zhang J, Keller ET, Namiki M. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. The Prostate. 67: 955-67. PMID 17440963 DOI: 10.1002/Pros.20581 |
0.426 |
|
| 2007 |
Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Research. 67: 3646-53. PMID 17440076 DOI: 10.1158/0008-5472.Can-06-1210 |
0.563 |
|
| 2007 |
Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Keller ET, Yao Z, Zhang J. PTHrP-induced MCP-1 production by human bone marrow endothelial cells and osteoblasts promotes osteoclast differentiation and prostate cancer cell proliferation and invasion in vitro. International Journal of Cancer. 121: 724-33. PMID 17390372 DOI: 10.1002/Ijc.22704 |
0.505 |
|
| 2007 |
Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C. Expression of the cytoskeleton linker protein ezrin in human cancers. Clinical & Experimental Metastasis. 24: 69-78. PMID 17370041 DOI: 10.1007/S10585-006-9050-X |
0.421 |
|
| 2007 |
Diehl KM, Keller ET, Ignatoski KM. Why should we still care about oncogenes? Molecular Cancer Therapeutics. 6: 418-27. PMID 17308043 DOI: 10.1158/1535-7163.Mct-06-0603 |
0.337 |
|
| 2007 |
Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, Zhang J. CCR2 expression correlates with prostate cancer progression. Journal of Cellular Biochemistry. 101: 676-85. PMID 17216598 DOI: 10.1002/Jcb.21220 |
0.514 |
|
| 2007 |
Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS. A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Research. 67: 149-59. PMID 17210694 DOI: 10.1158/0008-5472.Can-06-2971 |
0.406 |
|
| 2007 |
Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Medicine. 13: 62-9. PMID 17159986 DOI: 10.1038/Nm1519 |
0.418 |
|
| 2007 |
Kryczek I, Wei S, Keller E, Liu R, Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. American Journal of Physiology. Cell Physiology. 292: C987-95. PMID 16943240 DOI: 10.1152/Ajpcell.00406.2006 |
0.341 |
|
| 2006 |
Hall CL, Keller ET. The role of Wnts in bone metastases. Cancer Metastasis Reviews. 25: 551-8. PMID 17160558 DOI: 10.1007/S10555-006-9022-2 |
0.468 |
|
| 2006 |
Hall CL, Dai J, van Golen KL, Keller ET, Long MW. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Research. 66: 8648-54. PMID 16951179 DOI: 10.1158/0008-5472.Can-06-1544 |
0.553 |
|
| 2006 |
Asahi H, Mizokami A, Miwa S, Keller ET, Koshida K, Namiki M. Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. International Journal of Urology : Official Journal of the Japanese Urological Association. 13: 593-600. PMID 16771731 DOI: 10.1111/J.1442-2042.2006.01360.X |
0.543 |
|
| 2006 |
Beekman KW, Colevas AD, Cooney K, Dipaola R, Dunn RL, Gross M, Keller ET, Pienta KJ, Ryan CJ, Smith D, Hussain M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clinical Genitourinary Cancer. 4: 299-302. PMID 16729916 DOI: 10.3816/Cgc.2006.N.012 |
0.506 |
|
| 2006 |
Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung LW. Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. The American Journal of Pathology. 168: 1405-12. PMID 16651608 DOI: 10.2353/Ajpath.2006.050874 |
0.431 |
|
| 2006 |
Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Research. 66: 3087-95. PMID 16540658 DOI: 10.1158/0008-5472.Can-05-3447 |
0.484 |
|
| 2006 |
Hall CL, Kang S, MacDougald OA, Keller ET. Role of Wnts in prostate cancer bone metastases. Journal of Cellular Biochemistry. 97: 661-72. PMID 16447163 DOI: 10.1002/Jcb.20735 |
0.491 |
|
| 2006 |
Ershler WB, Artz AS, Keller ET. Issues of aging and geriatric medicine: relevance to cancer treatment and hematopoietic reconstitution. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 100-6. PMID 16399593 DOI: 10.1016/J.Bbmt.2005.10.007 |
0.313 |
|
| 2006 |
Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. The Prostate. 66: 248-56. PMID 16175585 DOI: 10.1002/Pros.20319 |
0.627 |
|
| 2006 |
Lyon MB, Stadler WM, Orvieto MA, Vander Griend DJ, Brendler CB, Steinberg GD, Kocherginsky MN, Keller ET, Willie MA, Rinker-Schaffer CW. 1194: Mitogen-Activated Protein Kinase Kinase 4 and RAF Kinase Inhibitory Protein Expression in Prostate Cancer: Role in Biochemical Failure after Radical Prostatectomy and Metastatic Lesions Journal of Urology. 175: 384-385. DOI: 10.1016/S0022-5347(18)33419-0 |
0.393 |
|
| 2005 |
Kitagawa Y, Dai J, Zhang J, Keller JM, Nor J, Yao Z, Keller ET. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Research. 65: 10921-9. PMID 16322239 DOI: 10.1158/0008-5472.Can-05-1809 |
0.512 |
|
| 2005 |
Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8232-41. PMID 16278478 DOI: 10.1200/Jco.2005.03.0841 |
0.561 |
|
| 2005 |
Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Research. 65: 8818-25. PMID 16204052 DOI: 10.1158/0008-5472.Can-05-0540 |
0.579 |
|
| 2005 |
Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Research. 65: 8274-85. PMID 16166304 DOI: 10.1158/0008-5472.Can-05-1891 |
0.563 |
|
| 2005 |
Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Research. 65: 7554-60. PMID 16140917 DOI: 10.1158/0008-5472.Can-05-1317 |
0.574 |
|
| 2005 |
Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer and Prostatic Diseases. 8: 253-9. PMID 15999121 DOI: 10.1038/Sj.Pcan.4500815 |
0.509 |
|
| 2005 |
Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 20: 318-29. PMID 15647826 DOI: 10.1359/Jbmr.041109 |
0.491 |
|
| 2005 |
Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology. 146: 1727-36. PMID 15637291 DOI: 10.1210/En.2004-1211 |
0.492 |
|
| 2005 |
Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. Journal of Cellular Biochemistry. 94: 273-8. PMID 15565643 DOI: 10.1002/Jcb.20169 |
0.634 |
|
| 2005 |
Dai J, Nor J, Keller E. Human Prostate cancer cells induce osteocalcin expression in the preosteoblast MC 3T3-E1 cell line through vascular endothelial growth factor (VEGF) The Japanese Journal of Urology. 96: 154. DOI: 10.5980/Jpnjurol.96.154_4 |
0.417 |
|
| 2004 |
Lu Y, Zhang J, Dai J, Dehne LA, Mizokami A, Yao Z, Keller ET. Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor. Clinical & Experimental Metastasis. 21: 399-408. PMID 15672864 DOI: 10.1007/S10585-005-0056-6 |
0.465 |
|
| 2004 |
Kiefer JA, Vessella RL, Quinn JE, Odman AM, Zhang J, Keller ET, Kostenuik PJ, Dunstan CR, Corey E. The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical & Experimental Metastasis. 21: 381-7. PMID 15672862 DOI: 10.1007/S10585-004-2869-0 |
0.497 |
|
| 2004 |
Keller ET, Fu Z, Brennan M. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochemical Pharmacology. 68: 1049-53. PMID 15313400 DOI: 10.1016/J.Bcp.2004.04.024 |
0.563 |
|
| 2004 |
Keller ET. Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). Anti-Cancer Drugs. 15: 663-9. PMID 15269597 DOI: 10.1097/01.Cad.0000136877.89057.B9 |
0.504 |
|
| 2004 |
Loberg RD, Fridman Y, Pienta BA, Keller ET, McCauley LK, Taichman RS, Pienta KJ. Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia (New York, N.Y.). 6: 302-9. PMID 15256052 DOI: 10.1593/Neo.03484 |
0.406 |
|
| 2004 |
Keller ET, Fu Z, Yeung K, Brennan M. Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene. Cancer Letters. 207: 131-7. PMID 15151133 DOI: 10.1016/J.Canlet.2004.02.006 |
0.678 |
|
| 2004 |
Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, Franceschi RT, D'Silva NJ, McCauley LK. Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. The Journal of Biological Chemistry. 279: 29121-9. PMID 15128746 DOI: 10.1074/Jbc.M313000200 |
0.346 |
|
| 2004 |
Zhang J, Lu Y, Dai J, Yao Z, Kitazawa R, Kitazawa S, Zhao X, Hall DE, Pienta KJ, Keller ET. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. The Prostate. 59: 360-9. PMID 15065084 DOI: 10.1002/Pros.20019 |
0.441 |
|
| 2004 |
Brown JM, Zhang J, Keller ET. Opg, RANKl, and RANK in cancer metastasis: expression and regulation. Cancer Treatment and Research. 118: 149-72. PMID 15043192 DOI: 10.1007/978-1-4419-9129-4_7 |
0.388 |
|
| 2004 |
Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. Journal of Cellular Biochemistry. 91: 718-29. PMID 14991763 DOI: 10.1002/Jcb.10662 |
0.563 |
|
| 2004 |
Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nör J, McCauley LK, Taichman RS, Keller ET. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Research. 64: 994-9. PMID 14871830 DOI: 10.1158/0008-5472.Can-03-1382 |
0.526 |
|
| 2004 |
Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, ... Keller ET, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. The Journal of Biological Chemistry. 279: 17515-23. PMID 14766752 DOI: 10.1074/Jbc.M313816200 |
0.598 |
|
| 2004 |
Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research. 64: 765-71. PMID 14744796 DOI: 10.1158/0008-5472.Can-03-0130 |
0.452 |
|
| 2004 |
Fu Z, Smith P, Zhang L, Rubin M, Dunn R, Yao Z, Keller E. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis Urologic Oncology: Seminars and Original Investigations. 22: 78-79. DOI: 10.1016/j.urolonc.2003.12.006 |
0.579 |
|
| 2003 |
Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Research. 63: 7883-90. PMID 14633717 |
0.373 |
|
| 2003 |
Pfitzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 18: 1882-8. PMID 14584899 DOI: 10.1359/Jbmr.2003.18.10.1882 |
0.483 |
|
| 2003 |
Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. Journal of the National Cancer Institute. 95: 878-89. PMID 12813171 DOI: 10.1016/J.Urolonc.2003.12.006 |
0.63 |
|
| 2003 |
Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J, Taichman RS, McCauley LK, Keller ET, Pienta KJ. Stromal factors involved in prostate carcinoma metastasis to bone. Cancer. 97: 739-47. PMID 12548571 DOI: 10.1002/Cncr.11181 |
0.472 |
|
| 2002 |
Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases Drugs of Today. 38: 91-102. PMID 12532187 DOI: 10.1358/Dot.2002.38.2.820105 |
0.571 |
|
| 2002 |
Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. The Prostate. 53: 232-40. PMID 12386924 DOI: 10.1002/Pros.10152 |
0.528 |
|
| 2002 |
Demiralp B, Chen HL, Koh AJ, Keller ET, McCauley LK. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology. 143: 4038-47. PMID 12239115 DOI: 10.1210/En.2002-220221 |
0.346 |
|
| 2002 |
Zhang J, Dai J, Lin DL, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 17: 1256-63. PMID 12096839 DOI: 10.1359/Jbmr.2002.17.7.1256 |
0.522 |
|
| 2002 |
Fu Z, Dozmorov IM, Keller ET. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. The Prostate. 51: 10-20. PMID 11920953 DOI: 10.1002/Pros.10056 |
0.684 |
|
| 2002 |
Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research. 62: 1832-7. PMID 11912162 |
0.473 |
|
| 2002 |
Zhang J, Johnston G, Stebler B, Keller ET. Hydrogen peroxide activates NFkappaB and the interleukin-6 promoter through NFkappaB-inducing kinase. Antioxidants & Redox Signaling. 3: 493-504. PMID 11491660 DOI: 10.1089/15230860152409121 |
0.314 |
|
| 2002 |
Stewart S, Shea DA, Tarnowski CP, Morris MD, Wang D, Franceschi R, Lin DL, Keller E. Trends in early mineralization of murine calvarial osteoblastic cultures: A Raman microscopic study Journal of Raman Spectroscopy. 33: 536-543. DOI: 10.1002/Jrs.892 |
0.345 |
|
| 2001 |
Keller ET, Zhang J, Cooper CR, Smith PC, McCauley LK, Pienta KJ, Taichman RS. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Reviews. 20: 333-49. PMID 12085970 DOI: 10.1023/A:1015599831232 |
0.508 |
|
| 2001 |
Richard V, Lairmore MD, Green PL, Feuer G, Erbe RS, Albrecht B, D'Souza C, Keller ET, Dai J, Rosol TJ. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression. The American Journal of Pathology. 158: 2219-28. PMID 11395400 DOI: 10.1016/S0002-9440(10)64694-9 |
0.36 |
|
| 2001 |
Smith PC, Keller ET. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. The Prostate. 48: 47-53. PMID 11391686 DOI: 10.1002/Pros.1080 |
0.478 |
|
| 2001 |
Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. The Journal of Clinical Investigation. 107: 1235-44. PMID 11375413 DOI: 10.1172/Jci11685 |
0.652 |
|
| 2001 |
Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, Keller ET. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. The Prostate. 47: 212-21. PMID 11351351 DOI: 10.1002/Pros.1065 |
0.523 |
|
| 2001 |
Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine & Growth Factor Reviews. 12: 33-40. PMID 11312117 DOI: 10.1016/S1359-6101(00)00021-6 |
0.48 |
|
| 2001 |
Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A. Long-term exposure of tumor necrosis factor alpha causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. The Prostate. 46: 319-26. PMID 11241555 DOI: 10.1002/1097-0045(20010301)46:4<319::Aid-Pros1039>3.0.Co;2-C |
0.492 |
|
| 2001 |
Yao Z, Zhang J, Dai J, Keller ET. Ethanol activates NFkappaB DNA binding and p56lck protein tyrosine kinase in human osteoblast-like cells. Bone. 28: 167-73. PMID 11182374 DOI: 10.1016/S8756-3282(00)00425-7 |
0.385 |
|
| 2000 |
Dai J, Lin D, Zhang J, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Chronic alcohol ingestion induces osteoclastogenesis and bone loss through IL-6 in mice. The Journal of Clinical Investigation. 106: 887-95. PMID 11018077 DOI: 10.1172/Jci10483 |
0.511 |
|
| 2000 |
Keller ET, Binkley NC, Stebler BA, Hall DM, Johnston GM, Zhang J, Ershler WB. Ovariectomy does not induce osteopenia through interleukin-6 in rhesus monkeys (Macaca mulatta). Bone. 26: 55-62. PMID 10617157 DOI: 10.1016/S8756-3282(99)00240-9 |
0.334 |
|
| 2000 |
MIZOKAMI A, GOTOH A, YAMADA H, KELLER ET, MATSUMOTO T. TUMOR NECROSIS FACTOR-α REPRESSES ANDROGEN SENSITIVITY IN THE LNCaP PROSTATE CANCER CELL LINE Journal of Urology. 164: 800-805. DOI: 10.1016/S0022-5347(05)67318-1 |
0.519 |
|
| 1999 |
Chiu KM, Keller ET, Crenshaw TD, Gravenstein S. Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. Calcified Tissue International. 64: 527-33. PMID 10341026 DOI: 10.1007/S002239900644 |
0.335 |
|
| 1998 |
Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, MacEwen EG. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer Human Gene Therapy. 9: 1851-1861. PMID 9741424 DOI: 10.1089/Hum.1998.9.13-1851 |
0.307 |
|
| 1998 |
Zhang J, Pugh TD, Stebler B, Ershler WB, Keller ET. Orchiectomy increases bone marrow interleukin-6 levels in mice. Calcified Tissue International. 62: 219-26. PMID 9501955 DOI: 10.1007/S002239900421 |
0.381 |
|
| 1998 |
Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Developmental and Comparative Immunology. 21: 487-99. PMID 9463782 DOI: 10.1016/S0145-305X(97)00029-3 |
0.328 |
|
| 1997 |
Keller ET, Zhang J, Ershler WB. Ethanol activates the interleukin-6 promoter in a human bone marrow stromal cell line. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 52: B311-7. PMID 9402932 DOI: 10.1093/Gerona/52A.6.B311 |
0.333 |
|
| 1996 |
Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Frontiers in Bioscience : a Journal and Virtual Library. 1: d59-71. PMID 9159212 DOI: 10.2741/A116 |
0.349 |
|
| 1996 |
Keller ET, Chang C, Ershler WB. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. The Journal of Biological Chemistry. 271: 26267-75. PMID 8824277 DOI: 10.1074/Jbc.271.42.26267 |
0.372 |
|
| 1995 |
Chang C, Saltzman A, Yeh S, Young W, Keller ET, Lee H, Wang C, Mizokami A. Androgen receptor: an overview. Critical Reviews in Eukaryotic Gene Expression. 5: 97-125. PMID 8845584 DOI: 10.1615/Critreveukargeneexpr.V5.I2.10 |
0.307 |
|
| Show low-probability matches. |